PDX Portal

Model Details

Patient Information for Model: HCI-023

Model Contact

Model: HCI-023
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: HCI-023

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

There are no omics data for this model.

Drug Studies for Model: HCI-023

Treatment Response Across All Studies

CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA

Drug Study: T123-T130

Study Metadata

Study ID: T123-T130
Study Type: Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms: 2
Mouse Strain:

PI: Alana Welm
Study Title: Tolinapant Efficacy Study
Treatments: Tolinapant
Study Duration:
Transplant Site
Transplant Material:

Study Design

Study Description	Arm Type	Treatment Arms	Number of Mice	Dose (mg/kg)	Concentration (mg/ml)	Vehicle	Route	Dosing Schedule
	Control	Vehicle
	Treatment	Tolinapant		20

Treatment Results

Treatment Arm	Treatment Duration	Monitoring Method	Monitor Duration	Tumor volume over time (%)	Response Category
Vehicle			21	609	PD
Tolinapant			21	-90	PR

Histology Information for Model: HCI-023

There are no histology images for this model.

Metastasis Information for Model: HCI-023

Patient

PDX

Abdomen

Adrenal gland

Bone

Bone (de novo)

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

LMD

Liver

Lung

Lymph node

Lymph nodes

Neck

None

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

medistinal and right hilar

Patient Treatment Information for Model: HCI-023

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response
10	Adriamycin/Cyclophosphamide, Paclitaxel	Adjuvant	54.25	54.5	91 days	Progressive disease
15	Olaparib	Adjuvant	54.67	55.91	453 days	Progressive disease
20	Xgeva	Adjuvant	54.68	54.99	113 days	Progressive disease
25	Carboplatin	Adjuvant	54.83	54.91	29 days	Progressive disease
30	PD1 inhibitor trial	Adjuvant	54.91	54.95	15 days	Progressive disease
40	Xeloda	Adjuvant	56.08	56.16	29 days	Progressive disease